# Integer Holdings Corp: Form 10-Q for the period ended Mar 29, 2013

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2013-05-07
- Accepted by EDGAR: May 7, 2013, 19:21 ET
- Period: 2013-03-29
- Accession: 0001193125-13-204203
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000119312513204203/d533159d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000119312513204203/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-03-29.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-12-29 to 2013-03-29 | $148.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2012-12-29 to 2013-03-29 | $99.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2012-12-29 to 2013-03-29 | $48.7m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2012-12-29 to 2013-03-29 | $20.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-12-29 to 2013-03-29 | $14.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-12-29 to 2013-03-29 | $7.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-12-29 to 2013-03-29 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-12-29 to 2013-03-29 | $5.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-12-29 to 2013-03-29 | $0.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-12-29 to 2013-03-29 | $0.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-12-29 to 2013-03-29 | 24,415,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2012-12-29 to 2013-03-29 | −$7.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-12-29 to 2013-03-29 | $6.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-03-29 | $10.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-03-29 | $271.7m | us-gaap:AssetsCurrent |
| Total assets | at 2013-03-29 | $884.9m | us-gaap:Assets |
| Current liabilities | at 2013-03-29 | $102.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-03-29 | $395.5m | us-gaap:Liabilities |
| Long-term debt | at 2013-03-29 | $233.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2013-03-29 | $489.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 50,941 characters.

### Our Business

We operate our business in two reportable segments – Implantable Medical and Electrochem Solutions (“Electrochem”). The Company’s customers include large multi-national original equipment manufacturers (“OEMs”). The Implantable Medical segment is comprised of our Greatbatch Medical and QiG Group and designs and manufactures medical devices and components for the cardiac, neuromodulation, vascular and orthopaedic markets. The Implantable Medical segment offers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution, which is facilitated through the QiG Group and leverages the component technology of Greatbatch Medical. The devices designed and developed by the QiG Group are manufactured by Greatbatch Medical. The Implantable Medical segment also offers individual components for implantable medical devices as well as value-added assembly and design engineering services for its component products. Examples of these components include batteries, capacitors, filtered and unfiltered feedthroughs, machined components, enclosures, leads, introducers, catheters, as well as orthopaedic implants, instruments and cases and trays.

Electrochem is an industry leader in designing and manufacturing total power solutions for critical applications with market-leading OEMs, largely in the portable medical and energy space. Electrochem offers its customers components, consultation, design, development and testing for medical device applications in high-value markets, including those that support the transition of delivery of health care from clinical to outpatient and home settings, as well as those that enhance the quality of life for an aging population. Examples of these devices include powered surgical tools, automated external defibrillators, portable ultrasound devices, portable oxygen concentrators, and ventilators, among others. Electrochem provides cell and battery pack configurations for rechargeable and non-rechargeable battery power systems, charging and docking stations, and power supplies, for devices where failure is not an option.

### Our Customers

Implantable Medical customers include leading OEMs, in alphabetical order here and throughout this report, such as Biotronik, Boston Scientific, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. The nature and extent of our selling relationships with each OEM varies in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. During the three months ended March 29, 2013, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 52% of our total Company sales.

Electrochem’s customers are primarily companies involved in demanding markets with sophisticated total power solutions needs, such as in the portable medical and energy markets. Some of Electrochem’s larger OEM customers are Phillips Healthcare, Physio-Control, Covidien, Ethicon Endo-Surgery, Carefusion, Halliburton and Weatherford International.

### Strategic and Financial Overview

As expected, first quarter 2013 revenue was lower than the prior year period. First quarter 2013 sales decreased $10.8 million or 7% over the prior year period to $148.3 million. This decrease was partially due to the sale of certain non-core orthopaedic product lines at the beginning of 2013, which caused orthopaedic revenue to decline by approximately $4.2 million. Foreign currency exchange rate fluctuations did not have a material impact on the current quarter in comparison to the prior year period. When adjusting for the sale of non-core product lines, 2013 first quarter revenue declined 4% compared to the prior year first quarter. This decline was primarily due to continued cardiac rhythm management (“CRM”) market headwinds, customer market share shifts, as well as customer inventory builds in the fourth quarter of 2012 for all product lines except orthopaedics. We saw the impact of fourth quarter 2012 inventory builds in lower first quarter 2013 orders. Orthopaedic revenue in the first quarter 2013, on a constant currency organic basis, grew 11% for the first quarter of 2013 due to implant market share gains and cases and tray product launches. This growth was partially offset by the timing of plant validations in connection with the closing of our Swiss facilities. For the remainder of 2013, we expect revenue to improve as customer ordering patterns normalize, orthopaedic backlog begins to be relieved, and new product introductions are commercialized in our cardiac and portable medical product lines.

\- 32 -

We prepare our consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) acquisition-related charges, (ii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iii) asset write-down and disposition charges, (iv) severance charges in connection with corporate realignments or a reduction in force, (v) litigation charges and gains, (vi) the impact of non-cash charges to interest expense due to the accounting change for convertible debt, (vii) unusual or infrequently occurring items, (viii) certain R&D expenditures (such as medical device design verification (“DVT”) expenses in connection with developing our neuromodulation platform), (ix) gain/loss on the sale of investments, (x) the income tax (benefit) related to these adjustments and (xi) certain tax charges related to the consolidation of our Swiss Orthopaedic facility. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, certain performance-based compensation incentives provided to our executives are determined utilizing these adjusted amounts.

A reconciliation of GAAP operating income to adjusted amounts is as follows (in thousands):

|  | Three Months Ended Implantable Medical Mar. 29, 2013 | Mar. 30, 2012 | Electrochem Mar. 29, 2013 | Mar. 30, 2012 | Unallocated Mar. 29, 2013 | Mar. 30, 2012 | Total Mar. 29 2013 | Mar. 30 2012 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | $111,414 | $117,817 | $36,851 | $41,286 | $— | $— | $148,265 | $159,103 |
| Operating income (loss) as reported | $14,343 | $10,112 | $4,816 | $4,471 | $(4,820) | $(3,385) | $14,339 | $11,198 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | — | 532 | — | — | — | 532 |
| Medical device DVT expenses (RD&E) | 1,734 | 1,040 | — | — | — | — | 1,734 | 1,040 |
| Consolidation and optimization costs | 2,760 | 750 | — | — | 302 | 818 | 3,062 | 1,568 |
| Acquisition and integration expenses | 70 | 105 | 40 | 838 | 1 | — | 111 | 943 |
| Asset dispositions, severance and other | 60 | (24) | 5 | 255 | — | 3 | 65 | 234 |
| Adjusted operating income (loss) | $18,967 | $11,983 | $4,861 | $6,096 | $(4,517) | $(2,564) | $19,311 | $15,515 |
| Adjusted operating margin | 17.0% | 10.2% | 13.2% | 14.8% | N/A | N/A | 13.0% | 9.8% |
| Medical device related adjusted expenses (excluding DVT) | $5,875 | $7,501 | $— | $— | $— | $— | $5,875 | $7,501 |
| Adjusted operating income excluding medical device related adjusted expenses | $24,842 | $19,484 | $4,861 | $6,096 | $(4,517) | $(2,564) | $25,186 | $23,016 |
| Adjusted operating margin excluding medical device related adjusted expenses | 22.3% | 16.5% | 13.2% | 14.8% | N/A | N/A | 17.0% | 14.5% |

\- 33 -

GAAP operating income for the first quarter 2013 was $14.3 million compared to $11.2 million for the comparable 2012 period. This increase was primarily due to increased gross profit and lower net research, development and engineering (“RD&E”) investments, partially offset by higher selling, general, and administrative (“SG&A”) expenses and consolidation and optimization expenses. Adjusted operating income, which excludes consolidation, optimization and DVT costs, increased 24% to $19.3 million compared to $15.5 million in first quarter 2012. The increase in gross profit was driven primarily by cost savings and production efficiencies, including savings realized from the consolidation of our Swiss orthopaedic facilities and product line rationalizations, which totaled approximately $1.3 million. The improvement in RD&E is primarily a result of our efforts, beginning in 2012, to focus medical device research and development (“R&D”) investments and discontinue certain non-core R&D projects as well as a higher level of customer cost reimbursements. The increase in SG&A was primarily due to the additional cost from our investment in sales and marketing resources to drive future core business growth. The increase was partially offset by synergies realized from our acquisitions and benefits from the Swiss orthopaedic facility consolidation.

GAAP and adjusted diluted EPS for the first quarter of 2013 were $0.23 and $0.44 per share, respectively, compared to $0.19 and $0.37 per share, respectively, for the first quarter 2012.

A reconciliation of GAAP net income and diluted EPS to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended March 29, 2013 Net Income (Loss) | Impact Per Diluted Share | March 30, 2012 Net Income (Loss) | Impact Per Diluted Share |
| --- | ---: | ---: | ---: | ---: |
| Net income as reported | $5,663 | $0.23 | $4,467 | $0.19 |
| Adjustments: |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | 346 | 0.01 |
| Medical device DVT expenses (RD&E) | 1,127 | 0.05 | 676 | 0.03 |
| Consolidation and optimization costs(a) | 2,340 | 0.10 | 1,019 | 0.04 |
| Acquisition and integration expenses | 72 | — | 613 | 0.03 |
| Asset dispositions, severance and other | 65 | — | 152 | 0.01 |
| Loss on cost and equity method investments, net(b) | 46 | — | — | — |
| CSN conversion option discount amortization(c) | 2,906 | 0.12 | 1,444 | 0.06 |
| 2012 R&D Tax Credit(d) | (1,500) | (0.06) | — | — |
| Adjusted net income and diluted EPS(e) | $10,719 | $0.44 | $8,717 | $0.37 |
| Adjusted diluted weighted average shares | 24,415 |  | 23,848 |  |

(a) Net of tax amounts computed using U.S. and foreign tax rates of 35% and 0%, respectively, for items incurred in those geographic locations for 2013 amounts and 35% and 22.5%, respectively for 2012 amounts.

(b) Pre-tax amount is $70 thousand for 2013.

(c) Pre-tax amount is $4.5 million for the 2013 period and $2.2 million for the 2012 period.

(d) Relates to the 2012 portion of the R&D tax credit which was reinstated in the first quarter of 2013 retroactive back to the beginning of 2012. As required, the full year impact of the R&D tax credit relating to 2012 was recognized in the first quarter of 2013.

(e) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

\- 34 -

### 2013 Financial Guidance

We are reaffirming our adjusted operating income as a percentage of sales and adjusted diluted EPS guidance ranges provided at the beginning of the year as follows:

|  |  |
| --- | --- |
| Adjusted Operating Income as a % of Sales | 12.0% - 12.5% |
| Adjusted Diluted EPS | $1.90 - $2.00 |

However, based on the actual results for the first quarter and our current expectations for the remainder of the year, we see a general trend towards the lower end of our original sales guidance of $660 million to $680 million provided at the beginning of the year. If achieved, this would result in organic revenue growth of 5% - 8% due to the disposition of $15 million of non-core orthopaedic product lines at the end of 2012.

As previously disclosed, adjusted operating income for 2013 includes GAAP operating income minus non-recurring, unusual or infrequently occurring items such as acquisition, consolidation and integration charges, certain RD&E expenditures, and asset disposition/write-down charges, totaling approximately $11.5 million to $14.0 million for 2013. These adjustments are significantly lower than the 2012 level as we have essentially completed our consolidation initiatives. Included in the above range are residual DVT costs in the range of $4.8 to $5.8 million to complete our Algostim project.

### Our CEO’s View

As expected, our first quarter 2013 revenue was lower than the prior year period, however, the magnitude of the decline in our sales was more than we anticipated. We are pleased with the performance of our orthopaedics product line, which had 11% organic growth. Additionally, we continue to expect new product introductions to drive second half 2013 portable medical growth and to sustain or slightly outperform the CRM market.

Despite the decrease in sales, we were able to achieve a 19% increase in our adjusted diluted EPS as a result of a 320 basis point improvement in our adjusted operating margin to 13.0%. This improvement reflects our plant consolidations and more focused RD&E investment, partially offset by our continued investment in sales and marketing resources. Our core business, which excludes $5.9 million of incremental medical device development expenses, posted a 17.0% adjusted operating margin performance.

We continue to make good progress on our key strategic initiatives which include:

- Successfully transferring orthopaedic manufacturing to our Fort Wayne and Tijuana facilities;
- Prioritizing and focusing our RD&E investment and discontinuing non-core projects;
- Continued milestone progress on our Algostim spinal cord stimulator positioning us for a second half 2013 PMA submission;
- On-going discussions with potential OEM partners for the commercialization of Algostim; and
- Maintaining and deepening our relationship with our OEM customers.

### Product Development

*Implantable Medical* - We provide our Implantable Medical customers with complete medical devices. This medical device strategy is being facilitated through the QiG Group and includes strategic equity investments and medical devices developed independently as well as in conjunction with our OEM partners. While we do not intend to discuss each of these projects individually each quarter, we will discuss significant milestones as they occur. Some of the medical device projects that we currently are working on include:

Cardiovascular portfolio – As previously disclosed, near the end of 2012, Greatbatch Medical voluntarily decided to perform a field action on two of its cardiovascular medical devices as a result of manufacturing irregularities observed during inspection. This problem was identified after implementing a new inspection tool for use in performing inspections. Revenue on these medical devices, which totaled $3.3 million in 2012, is expected to be temporarily delayed until the second half of 2013.

\- 35 -

Neuromodulation portfolio – With regards to Algostim, our spinal cord stimulator for the treatment of chronic pain in the trunk and limbs, DVT activities remain on track. During the first quarter of fiscal 2013, we initiated two animal studies for support of our literature-based PMA submission, which is anticipated later this year and we are well along on our CE mark submission with having completed the first three phases of a five phase modular submission with the TUV. Operationally, we are identifying and signing up key suppliers. Also, our collaboration with J.P. Morgan, who is assisting us in identifying commercial partners, is progressing well.

Approximately $0.5 million of the NeuroNexus Technologies, Inc. (“NeuroNexus”) acquisition purchase price in February 2012 was allocated to the estimated fair value of acquired in process research and development (“IPR&D”). These projects are expected to generate cash flows but have not yet reached technological feasibility, and thus were classified as an indefinite-lived intangible asset until the completion or abandonment of the associated projects. The value assigned to IPR&D related to the development of micro-electrodes for deep brain mapping and electrocorticography. There have been no significant changes from our original estimates with regards to these projects.

*Electrochem* - Electrochem continues to win new customers, new applications and next generation products. Our core competencies enable us to be well-positioned to win existing share and additional new product introductions based on our experience in providing solutions, our customer relationships, our investment in technology and facilities to further expand our capabilities, our capacity to service our customers, and our legacy of delivering highly reliable and innovative solutions to the medical marketplace.

The 2012 growth in Electrochem was driven by successful product launches into the higher growth, higher value portable medical market. Gaining better access to this attractive market is one of our strategic priorities as it provides us with a significant opportunity for growth given its $1 billion market size. Projections for growth in portable medical are expected to be double digit in 2013 with additional product launches with existing and new customers. Additionally, this market is benefiting from favorable market trends as patient care shifts from clinical settings to the home and as an aging population drives the need for lightweight and portable devices for patients and caregivers. These favorable trends are expected to allow this market to grow faster than our legacy markets over the next several years. Finally, this market is also attractive to us given that it has long product life cycles that should provide stability and diversification to our revenue base.

\- 36 -

### Cost Savings and Consolidation Efforts

In 2013 and 2012, we recorded charges in Other Operating Expenses, Net related to cost savings and consolidation efforts. These initiatives were undertaken to improve our operational efficiencies and profitability. Additional information regarding the timing, cash flow impact and amount of future expenditures is set forth in Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report, as well as the “Liquidity and Capital Resources” section of this Item.

Over the last three years, we have been implementing a multi-faceted plan to further enhance, optimize and leverage our orthopaedics operations. This plan includes the construction of an orthopaedic manufacturing facility in Fort Wayne, IN, updating our Indianapolis, IN facility to streamline operations, increase capacity, and further expand capabilities, and the transfer of most major functions performed at our facilities in Orvin and Corgemont, Switzerland into our Fort Wayne, IN and Tijuana, Mexico facilities. The total capital investment expected for these initiatives is between $25 million and $30 million, of which $21.2 million has been expended to date. Total expense expected to be incurred for these initiatives is between $36 million and $40 million, of which $35.8 million has been incurred to date.

Near the end of 2011, we initiated plans to optimize and expand our manufacturing infrastructure in order to support our medical device strategy. This included the transfer of certain product lines to lower cost facilities, expansion of two of our existing facilities, as well as the purchase of equipment to create additional capacity for the manufacture of medical devices and create additional cost savings. Total capital investment under these initiatives is expected to be between $15 million to $20 million, of which approximately $10.3 million has been expended to date. Total expenses expected to be incurred on these projects is between $2.0 million to $3.0 million, of which $1.6 million has been incurred to date.

These orthopaedic and medical device initiatives are expected to be completed over the next year and are expected to generate approximately $10 million to $15 million of annual cost savings and increase our capacity in order to support our growth and the manufacturing of complete medical devices.

In 2011, we initiated plans to upgrade our existing global ERP system. This initiative is expected to be completed over the next year. Total capital investment under this initiative is expected to be approximately $4 million to $5 million, of which approximately $3.0 million has been expended to date. Total expenses expected to be incurred on this initiative is between $6 million to $7 million, of which $5.3 million has been incurred to date.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The first quarter of 2013 and 2012 ended on March 29, and March 30, respectively, and each contained 13 weeks. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2012.

\- 37 -

The following table presents certain financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Implantable Medical | Three Months Ended March 29, 2013 | March 30, 2012 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardiac/Neuromodulation | $71,167 | $75,135 | $(3,968) | -5% |
| Vascular | 10,624 | 11,636 | (1,012) | -9% |
| Orthopaedic | 29,623 | 31,046 | (1,423) | -5% |
| Total Implantable Medical | 111,414 | 117,817 | (6,403) | -5% |
| Electrochem |  |  |  |  |
| Portable Medical | 18,889 | 18,720 | 169 | 1% |
| Energy | 12,293 | 14,771 | (2,478) | -17% |
| Other | 5,669 | 7,795 | (2,126) | -27% |
| Total Electrochem | 36,851 | 41,286 | (4,435) | -11% |
| Total sales | 148,265 | 159,103 | (10,838) | -7% |
| Cost of sales | 99,516 | 112,215 | (12,699) | -11% |
| Gross profit | 48,749 | 46,888 | 1,861 | 4% |
| Gross profit as a % of sales | 32.9% | 29.5% |  |  |
| Selling, general and administrative expenses (SG&A) | 20,092 | 19,034 | 1,058 | 6% |
| SG&A as a % of sales | 13.6% | 12.0% |  |  |
| Research, development and engineering costs, net (RD&E) | 11,080 | 13,911 | (2,831) | -20% |
| RD&E as a % of sales | 7.5% | 8.7% |  |  |
| Other operating expense, net | 3,238 | 2,745 | 493 | 18% |
| Operating income | 14,339 | 11,198 | 3,141 | 28% |
| Operating margin | 9.7% | 7.0% |  |  |
| Interest expense | 6,988 | 4,359 | 2,629 | 60% |
| Other expense, net | 285 | 720 | (435) | -60% |
| Provision for income taxes | 1,403 | 1,652 | (249) | -15% |
| Effective tax rate | 19.9% | 27.0% |  |  |
| Net income | $5,663 | $4,467 | $1,196 | 27% |
| Net margin | 3.8% | 2.8% |  |  |
| Diluted earnings per share | $0.23 | $0.19 | $0.04 | 21% |

\- 38 -

### Sales

***Implantable Medical –*** Cardiac and neuromodulation sales for the first quarter of 2013 decreased 5% compared to the prior year period to $71.2 million. This decrease was primarily due to continued CRM market headwinds, OEM market share shifts, and customer inventory adjustments during the first quarter of 2013 due to inventory builds at the end of 2012. We remain cautiously optimistic with the prospects of this product line as we expect customer ordering patterns to return to more normalized levels and as we expect new battery product launches in the second half of 2013. Additionally, our longer-term outlook remains optimistic as we continue to see an increased pace of product development opportunities from our cardiac customers. We believe that these opportunities, combined with our increased sales and marketing resources, will allow the Company to grow this product line faster than the underlying market.

First quarter 2013 vascular sales decreased 9% to $10.6 million compared to the prior year period and was primarily due to customer inventory adjustments. Vascular revenue is expected to return to a more normalized level beginning in the second half of 2013. However, growth in this product line for the remainder of the year will be challenged by the previously communicated voluntary field action related to two vascular medical devices near the end of 2012. These devices are on track to be back on the market in the third quarter of 2013.

Orthopaedic sales of $29.6 million for the first quarter of 2013 declined 5% compared to the first quarter of 2012. During the first quarter of 2013, the Company sold certain non-core orthopaedic product lines which reduced orthopaedic revenue by approximately $4.2 million in comparison to the prior year period. Foreign currency exchange rate fluctuations did not have a material impact on the current quarter. On a constant currency organic basis, orthopaedic product line sales increased 11% in comparison to the prior year first quarter. This increase was primarily due to orthopaedic implant market share gains and cases and tray product launches and was partially offset by the timing of plant validations in connection with the transfer of operations from our Swiss facilities to other Greatbatch facilities. This consolidation has been completed and is expected to benefit the next two quarters as backlog is relieved.

***Electrochem –*** First quarter sales for Electrochem declined 11% to $36.9 million compared to $41.3 million for the comparable 2012 period. This decrease was primarily a result of tough comparables in our energy and other product lines. Additionally, inventory builds and product launches in the fourth quarter of 2012 impacted first quarter 2013 revenues resulting in customers having lower ordering levels. Our portable medical product line revenue grew 1% which was primarily driven by new product launches. Customer inventory depletion and new product launches will be key drivers to growth for the remainder of the year. Building a strong funnel of future opportunities continues to be a focus while investment in sales and marketing is driving long-term growth with new and existing customers. We continue to see strong market shifts that align with our capabilities to provide solutions to a broad range of opportunities within the portable medical market. We continue to leverage new technology developments that are opening up solutions throughout the patient care cycle from first responders, surgery, monitoring and recovery.

\- 39 -

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year period were due to the following:

|  | Change From Prior Year Three Months |
| --- | ---: |
| Impact of Swiss consolidations(a) | 0.9% |
| Cost savings and production efficiencies(b) | 3.1% |
| Selling price(c) | -1.0% |
| Other | 0.4% |
| Total percentage point change to gross profit as a percentage of sales | 3.4% |

(a) Our gross profit percentage benefitted approximately $1.3 million from the consolidation of our Swiss orthopaedic facilities into other existing Greatbatch facilities in the first quarter of 2013. The 2012 gross profit percentage includes the negative impact of production inefficiencies at those facilities.

(b) Our gross profit percentage benefitted from production efficiencies gained at our manufacturing facilities as a result of our various lean and supply chain initiatives as well as higher production volumes due to increased inventory levels.

(c) Our gross profit percentage has been negatively impacted in comparison to the prior year period by price concessions made to our larger OEM customers, which were given in exchange for long-term contracts.

Over the short-term, we expect to see continued year over year gross margin improvements as a result of the consolidation of our orthopaedic operations and from various other productivity improvement initiatives that are being implemented (See Cost Savings and Consolidation Efforts section). Additionally, over the long-term we expect our gross profit margin to improve as more system and device level products are introduced, which typically earn a higher margin.

### SG&A Expenses

Changes to SG&A expenses from the prior year period were due to the following (in thousands):

|  | Change From Prior Year Three Months |
| --- | ---: |
| Selling and marketing(a) | $713 |
| Performance-based compensation(b) | 624 |
| Other | (279) |
| Net increase in SG&A | $1,058 |

(a) Amount represents the incremental SG&A expenses related to our decision in 2012 to increase selling and marketing resources in order to drive core business growth and sustain a pipeline in order to achieve our committed 5% or better revenue growth performance goal.

(b) Amounts represent the change in performance-based compensation versus the prior year period and is recorded based upon the actual results achieved.

\- 40 -

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended March 29, 2013 | March 30, 2012 |
| --- | ---: | ---: |
| Research and development costs | $3,335 | $5,655 |
| Engineering costs | 10,958 | 9,639 |
| Less cost reimbursements | (3,213) | (1,383) |
| Engineering costs, net | 7,745 | 8,256 |
| Total RD&E, net | $11,080 | $13,911 |

Net RD&E for the 2013 first quarter decreased $2.8 million to $11.1 million in comparison to the first quarter of 2012. This improvement is primarily a result of the Company’s efforts, beginning in 2012, to focus medical device R&D investments and discontinuing certain non-core R&D projects. Additionally, first quarter 2013 results included $1.8 million of additional customer cost reimbursements due to the timing of achieving milestone payments on certain projects. These benefits were partially offset by higher DVT costs incurred in connection with the Company’s development of a neuromodulation platform. DVT expenses totaled $1.7 million for the first quarter of 2013 compared to $1.0 million for the comparable 2012 period. In total, medical device related expenses declined $0.9 million from the first quarter of 2012 to the first quarter of 2013. Going forward, the Company’s medical device technology investment is focused on successfully commercializing Algostim and being selective in opportunities that leverage our strengths in the core business units and drive exceptional and sustainable growth. Additionally, the Company continues to seek strategic partners to share in the costs of RD&E and reduce the impact on the bottom line.

### Other Operating Expense, Net

Other operating expense, net is comprised of the following (in thousands):

|  | Three Months Ended March 29, 2013 | March 30, 2012 |
| --- | ---: | ---: |
| Orthopaedic facility optimization(a) | $2,636 | $344 |
| Medical device facility optimization(a) | 105 | 329 |
| ERP system upgrade(a) | 321 | 895 |
| Acquisition and integration costs(b) | 111 | 943 |
| Asset dispositions, severance and other(c) | 65 | 234 |
| Total other operating expenses, net | $3,238 | $2,745 |

(a) Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating Expense, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During 2013 and 2012, we incurred costs related to the integration of Micro Power Electronics, Inc. and NeuroNexus. These expenses were primarily for retention bonuses, travel costs in connection with integration efforts, training, severance, and the change in fair value of the contingent consideration recorded in connection with these acquisitions.

\- 41 -

(c) During 2013 and 2012, we recorded write-downs in connection with various asset disposals, net of insurance proceeds received, if any.

### Interest Expense and Interest Income

Interest expense for the first quarter of 2013 increased $2.6 million over the comparable period of 2012, due to the increased discount amortization related to our convertible subordinated notes. This discount was being amortized utilizing the effective interest method and a portion was accelerated into the first quarter of 2013 from the second quarter of 2013 due to the redemption of those notes in the current period. As a result, interest expense is expected to decline for the remainder of 2013 in comparison to the respective periods of 2012.

### Other Expense, Net

Other expense, net primarily includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies. We generally do not expect foreign currency exchange rate fluctuations to have a material impact on our financial results.

### Provision for Income Taxes

The effective tax rate (including discrete items) for the first quarter of 2013 was 19.9% compared to 27.0% for the same period of 2012. This decrease was primarily attributable to the reinstatement of the R&D tax credit in the first quarter of 2013, as well as higher income in lower tax rate jurisdictions. During the first quarter of 2013, the Company recognized a $1.5 million discrete tax benefit related to the 2012 portion of the R&D tax credit. This benefit was partially offset by other discrete tax items recognized during the quarter. Overall the discrete tax items recognized in the first quarter of 2013 were consistent with those recognized in the first quarter of 2012. The benefit of the 2013 portion of the R&D tax credit will be recognized through the fiscal 2013 effective tax rate.

We currently expect our 2013 annual GAAP effective tax rate to be in the range of 30 to 33%. We expect there to be continued volatility of this effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

### Government Regulation

The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislated broad-based changes to the U.S. health care system that could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Health Care Reform imposes significant new taxes on medical device OEMs, which will result in a significant increase in the tax burden on our industry and which could have a material negative impact on our financial condition, results of operations and our cash flows. Other elements of Health Care Reform such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions could meaningfully change the way healthcare is developed and delivered, and may materially impact numerous aspects of our business, results of operations and financial condition. Many significant parts of Health Care Reform will be phased in over the next several years and require further guidance and clarification in the form of regulations. Management has evaluated the impact that the new medical device tax will have on our results from operations, which began in 2013, and has estimated that it will reduce gross profit by $0.6 million to $1.0 million.

\- 42 -

On August 22, 2012, the U.S. Securities and Exchange Commission (“SEC”) issued a rule under Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act requiring companies to publicly disclose their use of conflict minerals that originated in the Democratic Republic of the Congo (“DRC”) or an adjoining country. Under the rule, issuers are required to conduct a “reasonable” due diligence process to ascertain the source of conflict minerals, defined as tantalum, tin, gold or tungsten, that are necessary to the functionality or production of their manufactured or contracted to be manufactured products. Companies are required to provide this disclosure on a new form to be filed with the SEC called Form SD. Companies are required to file Form SD on May 31, 2014 for the 2013 calendar period and annually on May 31 every year thereafter. We anticipate additional, new compliance costs to be incurred since we utilize all of the minerals specified in the rule. We are unable to quantify the cost of implementing this new regulation at this time.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of March 29, 2013 | December 28, 2012 |
| --- | ---: | ---: |
| Cash and cash equivalents | $10,144 | $20,284 |
| Working capital | $169,181 | $176,376 |
| Current ratio | 2.65 | 2.92 |

The decrease in cash and cash equivalents from the end of 2012 was primarily due to cash used in operations of $7.6 million during the quarter. This cash usage was primarily a result of the buildup of inventory during the quarter in order to replenish safety stock levels and in anticipation of higher sales in the second half of the year, as well as the decrease in accrued expenses due to 2012 incentive compensation payments and severance payments made during the quarter in connection with our Swiss orthopaedic consolidation. The decrease in working capital and current ratio from the end of 2012 was a result of the variances discussed above as well as the reclassification of $30.4 million of deferred income taxes to income taxes payable as a result of the repayment of our convertible subordinated notes during the quarter. Of the $10.1 million of cash on hand as of March 29, 2013, $3.6 million is being held at our foreign subsidiaries.

***Revolving Line of Credit –*** We have a senior credit facility (the “Credit Facility”) consisting of a $400 million revolving line of credit, which can be increased to $600 million upon our request and approval by the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. The Credit Facility has a maturity date of June 24, 2016.

The Credit Facility is supported by a consortium of fourteen banks with no bank controlling more than 19% of the facility. As of March 29, 2013, each bank supporting the Credit Facility has an S&P credit rating of BBB or better, which is considered investment grade.

The Credit Facility requires us to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0. For the twelve month period ended March 29, 2013, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was 17.9 to 1.0, well above the required ratio. The Credit Facility also requires us to maintain a total leverage ratio of not greater than 4.0 to 1.0. As of March 29, 2013, our total leverage ratio, calculated in accordance with our credit agreement, was 2.34 to 1.0, well below the required ratio.

\- 43 -

The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for a more detailed description of the Credit Facility.

As of March 29, 2013, we had $167 million of borrowing capacity available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations discussed above. We believe that our cash flow from operations and the Credit Facility provide adequate liquidity to meet our short- and long- term funding needs.

***Operating activities –*** Cash used in operations for the first three months of 2013 was $7.6 million, which was higher than the usage in the comparable 2012 period of $0.4 million. This increase was primarily due to the buildup of inventory during the quarter in order to replenish safety stock levels and in anticipation of higher sales in the second half of the year. Additionally, the Company made severance payments during the quarter ended March 29, 2013 of $6.1 million in connection with our Swiss orthopaedic consolidation.

***Investing activities –*** Net cash used in investing activities for the first three months of 2013 was $5.8 million. This included $1.8 million of proceeds received from the sale of our Swiss orthopaedic product lines which closed during the first quarter of 2013. The proceeds received were offset by $6.7 million used for the purchase of property, plant and equipment to support normal operations as well as our cost savings and consolidation initiatives. Our current expectation is that capital spending for the full year of 2013 will be in the range of $20 million to $30 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flow from operations and availability under our Credit Facility will be sufficient to fund these capital expenditures. As part of our growth strategy, we have and will continue to consider targeted and opportunistic acquisitions.

***Financing activities –*** Net cash provided by financing activities for the first three months of 2013 was $3.3 million compared to $0.1 million for the prior year period. During the first quarter of 2013, we retired $198 million of convertible subordinated notes through the usage of its Credit Facility, resulting in a net borrowing of $2.2 million. Additionally, the Company received $1.2 million from stock option exercises that occurred during the first quarter of 2013. Going forward, we expect excess cash flow from operations to be used to fund our remaining consolidation initiatives and to pay down outstanding debt.

***Capital Structure –*** As of March 29, 2013, our capital structure consisted of $233 million of debt under our Credit Facility and 23.9 million shares of common stock outstanding. Additionally, we had $10.1 million in cash and cash equivalents, which is sufficient to meet our short-term operating cash needs. If necessary, we currently have access to $167 million under our Credit Facility and are authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. We believe that if needed we can access public markets to raise additional capital. We believe that our capital structure provides adequate funding to meet our growth objectives. We continuously evaluate our capital structure as it relates to our anticipated long-term funding needs. Changes to our capital structure may occur as a result of this analysis, or changes in market conditions.

\- 44 -

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Contractual Obligations

The following table summarizes our significant contractual obligations at March 29, 2013:

| CONTRACTUAL OBLIGATIONS | Payments due by period Total | Remainder of 2013 | 2014 -2015 | 2016 -2017 | After 2017 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt obligations(a) | $284,601 | $33,866 | $11,754 | $237,764 | $1,217 |
| Operating lease obligations(b) | 18,072 | 3,516 | 8,204 | 4,419 | 1,933 |
| Purchase obligations(b) | 29,006 | 16,483 | 8,223 | 4,180 | 120 |
| Foreign currency contracts(b) | 9,000 | 9,000 | — | — | — |
| Defined benefit plan obligations(c) | 4,288 | 302 | 787 | 888 | 2,311 |
| Total contractual obligations | $344,967 | $63,167 | $28,968 | $247,251 | $5,581 |

(a) Includes expected interest expense on the $233 million outstanding on our Credit Facility based upon the period end weighted average interest rate of 2.00%, which includes the impact of our interest rate swap agreement. Also includes $36.5 million of current and deferred federal and state taxes on the Company’s convertible subordinated notes of which $30.4 million will be paid during 2013. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information.

(b) See Note 11 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information about our operating leases, purchase obligations and foreign currency contracts.

(c) See Note 7 “Defined Benefit Plans” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information about our defined benefit plan obligations. During 2012, we transferred most major functions performed at our facilities in Switzerland into other existing facilities. As a result of this decision, we curtailed our defined benefit plan provided to employees at those facilities in the third quarter of 2012. As nearly all of the Swiss pension liability is expected to be paid off in 2013, the Company moved all Swiss pension plan assets into cash accounts during 2012. Swiss plan assets are expected to be sufficient to cover plan liabilities.

This table does not reflect $1.1 million of unrecognized tax benefits as we are uncertain as to if or when such amounts may be settled. Refer to Note 10 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information about these unrecognized tax benefits.

We self-fund the medical insurance coverage provided to our U.S. based employees. The Company’s risk is being limited through the use of stop loss insurance, which has specific stop loss coverage per associate for claims in the year exceeding $225 thousand per associate with no annual maximum aggregate stop loss coverage. As of March 29, 2013, we have $1.5 million accrued related to our self-insured medical plan, which is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet, and is primarily based upon claim history. This table does not reflect any potential future payments for self-insured medical claims.

\- 45 -

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), SEC, Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Condensed Consolidated Financial Statements. Based upon this review, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to the Condensed Consolidated Financial Statements in Item 1 of this report for additional information.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and industry;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within our markets and to offer products and services that meet the changing needs of those markets; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the SEC.

\- 46 -

## Market risk

As filed, 4,884 characters.

***Foreign Currency –*** We have significant foreign operations in France, Mexico and Switzerland, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Mexican pesos and Swiss francs, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange rate contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $7 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during the three months ended March 29, 2013 did not have a material impact in comparison to the prior year period.

In May 2012, we entered into two forward contracts to purchase 6.9 million and 7.2 million Mexican pesos per month beginning in January 2013 through December 2013 at an exchange rate of $0.0727 and $0.0693 per peso, respectively. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with a portion of the operations at our Tijuana, Mexico facility for 2013 and are being accounted for as cash flow hedges. As of March 29, 2013, these contracts had a positive fair value of $1.2 million, which is recorded within Prepaid Expenses and Other Current Assets in the Condensed Consolidated Balance Sheet. The amount recorded as a reduction of Cost of Sales during the three months ended March 29, 2013 and an increase of Cost of Sales during the three months ended March 30, 2012 related to our forward contracts was $0.2 million and $0.1 million, respectively. No portion of the change in fair value of our foreign currency exchange rate contracts during the three months ended March 29, 2013 or March 30, 2012 was considered ineffective.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income. The translation adjustment for the first quarter of 2013 was a $3.1 million loss compared to a $4.0 million gain for the first quarter of 2012. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other Expense, Net amounted to a loss of $0.05 million and $0.6 million for the first quarters of 2013 and 2012, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $8.0 million on our foreign net assets as of March 29, 2013.

***Interest Rates –*** Interest rates on our Credit Facility reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. To help offset this risk, from time to time, we enter into receive floating-pay fixed interest rate swaps indexed to the same applicable index rate as the debt it is hedging. In October 2012 we entered into a three-year $150 million interest rate swap, which amortizes $50 million per year, which became effective during the first quarter of 2013. Under terms of the contract, we receive a floating interest rate indexed to the one-month LIBOR rate and pay a fixed interest rate of 0.573%. This swap was entered into in order to hedge against potential changes in cash flows on the outstanding debt on the Credit Facility, due to the repayment of our convertible subordinated notes, which is also indexed to the one-month LIBOR rate. The receive variable leg of the interest rate swap and the variable rate paid on the debt is expected to have the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. This swap is accounted for as a cash flow hedge.

\- 47 -

As of March 29, 2013, we had $233 million outstanding on our revolving line of credit of which $150 million is currently being hedged. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in Item 1 of this report for additional information about our outstanding debt. A hypothetical one percentage point (100 basis points) change in the prime rate on the $83 million of unhedged floating rate debt outstanding at March 29, 2013 would have an impact of approximately $0.8 million on our interest expense.

## Controls and procedures

As filed, 2,464 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of March 29, 2013. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of March 29, 2013, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting.

We completed the acquisition of NeuroNexus Technologies, Inc. (“NeuroNexus”) on February 16, 2012. We believe that the internal controls and procedures of NeuroNexus are reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of NeuroNexus into our internal controls over financial reporting.

The Company continues to extend its Section 404 compliance program under the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules and regulations under such Act to include NeuroNexus. However, the Company has excluded NeuroNexus from management’s assessment of the effectiveness of internal control over financial reporting as of December 28, 2012, as permitted by the guidance issued by the Office of the Chief Accountant of the SEC. The Company will report on its assessment of the internal controls of its combined operations within the time period provided by the Act and the applicable SEC rules and regulations concerning business combinations.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

\- 48 -

## Risk factors

As filed, 159 characters.

There have been no material changes from risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 28, 2012.

Filed May 7, 2013.
Source: SEC EDGAR, the filing index for accession 0001193125-13-204203. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
